You get off a twenty-four-hour shift at seven in the morning. The last call is still riding around in your head. You have been meaning to deal with the heaviness for about two years, and the question that stops you is not whether to get help. It is where, and when, and how you fit it around a rotation that never holds still.

We put that question, where treatment actually happens, to 443 adults in ten Midwest states, in a summer survey funded by our publisher. The answers are worth knowing before you start calling around.

What people told us about the setting

We asked a general-population panel which setting they would pick for a newer depression treatment in the ketamine family. Here is how the final validated answers fell:

  • A nearby clinic, face to face: 44 percent
  • Telehealth, from their own home: 22 percent
  • Clinic to start, then home: 23 percent
  • Did not mind either way: 11 percent

Adding the first and third answers, 67 percent of respondents, combined, wanted a clinic in the mix somewhere. The at-home crowd was real, but it was the smaller camp.

This was a general sample, not a poll of police, fire, or EMS. About 7 percent of the people answering, 29 of 443, called themselves a veteran or first responder, a group too small to break out, so treat these numbers as the lay of the land rather than a read on responders.

Start by knowing which treatment you mean

The words "ketamine therapy" cover several very different things, and the setting is often decided by the treatment itself, not by your preference.

  • Esketamine (Spravato). Approved by the FDA as a nasal spray for depression that stubbornly resists standard treatment. Nobody hands you a bottle to take home. You take it in a certified healthcare setting and stay under observation for a monitoring period afterward, typically about two hours. Driving waits until the following day.
  • IV ketamine in a clinic. Generic ketamine given by infusion. For depression it is off-label: the drug's approval is for anesthesia, and the clinician is choosing this use. Insurance coverage is uncommon.
  • At-home ketamine. Mostly lozenges or pills, sent out after a telehealth visit and taken on your own couch. This is the grayest of the three. Oversight varies widely from one company to the next.

If a clinic or website blurs these together, treat that as your first warning sign. For the approved option, Brain Recovery Centers has a plain explanation of Spravato care.

Where responders can actually start

You do not need to find a ketamine provider first. In our data, the most common first stop was a person's own primary doctor, named by 56 percent, followed by a psychiatrist or mental health provider at 23 percent. That path works for responders too, and there are a few doors that are specific to your line of work.

  • Your department's employee assistance program. An EAP can usually get you a handful of free, confidential counseling sessions and a referral. Ask plainly whether the counselor can coordinate with a psychiatrist.
  • Peer support. Many agencies have trained peer teams. They cannot prescribe anything, but they often can name local clinicians who get shift work and critical incidents.
  • Your union or association health plan. Phone the member line printed on your card and request behavioral health specifically, not the general queue.

Matching the setting to a rotating schedule

If the treatment is Spravato, the in-clinic part is not optional. Early courses often involve more than one visit a week at first, then fewer. Each session includes the monitoring period and a ban on driving until the next day after a real night of sleep. For someone working 24s or rotating nights, that means you need a ride and a gap in the schedule. Ask the clinic how early their first appointment is and whether they can lock in a recurring slot that fits your days off.

If you are weighing a clinic-then-home model, the in-person part usually covers evaluation and any treatment that requires supervision, and the at-home part covers follow-ups and therapy by video. Find out which visits have to happen in the building and which can switch to video on short notice.

If you are looking at an at-home ketamine company, ask who screens you, whether a physician reviews your full history, what happens if you have a bad reaction at 2 a.m., and whether anyone is required to be with you during a dose. If the answers are vague, walk away.

Privacy is a fair question to ask

Plenty of responders worry about who will find out. That concern is not unusual. When we asked people to name the two things that mattered most in choosing a provider, 11 percent picked private and discreet care. Another 10 percent wanted a provider focused on veterans or first responders.

Coverage towered over every other factor. A full 85 percent listed insurance coverage as one of their two priorities, while nearness to home trailed far behind at 43 percent.

Questions worth asking any clinic before you book:

  • Who sees my records, and will anything be shared with my employer without my written consent?
  • If I need a fitness-for-duty letter, who writes it and what does it say?
  • Which treatments do you offer, and which are FDA-approved for my condition?

The honest limits

This is not medical advice, and nobody can promise that a given treatment will work for you. Esketamine is approved for a narrow purpose, mainly depression that has outlasted standard antidepressants, and only a clinician who has examined you can say whether your history fits. PTSD is not an approved use for Spravato, and a provider who suggests otherwise is overselling.

You are not alone in the struggle, either: 72 percent of respondents told us standard medication had failed them, someone they love, or both, for depression, anxiety, or PTSD.

If what you haul home from a shift ever becomes thoughts of ending your life, do not wait for a day off. Call or text 988 from any phone in the country; Suicide and Crisis Lifeline counselors answer on every shift, at every hour.

Methodology

Funding and commissioning both came from our publisher. Pollfish collected responses through its consumer panel until June 23, 2026, ending at n=443, all adults aged 18 to 64 from Ohio, Indiana, Illinois, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, and Oklahoma. It was not a survey of first responders, whose numbers were too small to report as a group. The figures are Pollfish's final, validated counts.